Marina Mitrović

Prof. Dr. Marina Mitrović

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MMMarina Mitrović
Marina Mitrović
DSDragica Selakovic
Dragica Selakovic
NJNemanja Jovicic
Nemanja Jovicic
BLBiljana Ljujic
Biljana Ljujic
GRGvozden Rosic
Gvozden Rosic
The neurotrophic system includes neurotrophins, such as brain-derived neurotrophic factor (BDNF) and its precursor proBDNF, which play conflicting roles in neuronal survival and apoptosis, with their balance having a significant impact on neurodegenerative outcomes. While BDNF is widely acknowledged as a potent neurotrophin that promotes neuronal survival and differentiation, its precursor, proBDNF, has the opposite effect, promoting apoptosis and neuronal death. This review highlights the new and unique aspects of BDNF/proBDNF interaction in the modulation of neuronal apoptotic pathways in neurodegenerative disorders. It systematically discusses the cross-talk in apoptotic signaling at the molecular level, whereby BDNF activates survival pathways such as PI3K/Akt and MAPK/ERK, whereas proBDNF activates p75NTR and sortilin to induce neuronal apoptosis via JNK, RhoA, NFkB, and Rac-GTPase pathways such as caspase activation and mitochondrial injury. Moreover, this review emphasizes the factors that affect the balance between proBDNF and BDNF levels within the context of neurodegeneration, including proteolytic processing, the expression of TrkB and p75NTR receptors, and extrinsic gene transcription regulators. Cellular injury, stress, or signaling pathway alterations can disrupt the balance of BDNF/proBDNF, which may be involved in apoptotic-related neurodegenerative diseases like Alzheimer’s, Parkinson’s, and Huntington’s diseases. This review provides a comprehensive framework for targeting neurotrophin signaling in the development of innovative therapies for neuronal survival and managing apoptotic-related neurodegenerative disorders, addressing the mechanistic complexity and clinical feasibility of BDNF/proBDNF interaction.

1 August 2017 in Cytokine
Verified
Journal Article
Closed access
Dejan BaskicDejan Baskic
Dejan Baskic
VVVuk R. Vukovic
Vuk R. Vukovic
Suzana Lj. PopovićSuzana Lj. Popović
Suzana Lj. Popović
PDPredrag Djurdjevic
Predrag Djurdjevic
MZMilan Zaric
Milan Zaric
ZMZeljko Mijailovic
Zeljko Mijailovic

19 February 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ALAleksandar Lazović
Aleksandar Lazović
BMBojana Simovic Markovic
Bojana Simovic Markovic
Irfan CorovicIrfan Corovic
Irfan Corovic
TMTijana Marković
Tijana Marković
MAMarija Andjelkovic
Marija Andjelkovic
MMMarina Mitrović
Marina Mitrović
Triple-negative breast cancer (TNBC), a highly invasive type of cancer, is difficult to treat due to insufficient specific targets and low survival rates. Current therapy often encounters drug resistance or relapse; thus, repurposing existing drugs could revolutionize cancer treatment. This study examined the anticancer effects of the antipsychotics Cariprazine (CAR), Olanzapine (OLZ), and Clozapine (CLZ), and the immunomodulatory potential of CAR, in vitro and in vivo in TNBC models. In vitro, CAR, OLZ, and CLZ significantly inhibited the proliferation of TNBC cells. This inhibition occurred via the induction of mitochondrial apoptosis, G0/G1 cell cycle arrest, and the suppression of autophagy, as evidenced by the down-regulation of Bcl-2, p62, and pAKT; the upregulation of Bax and active caspase 3; the decrease of ΔΨM; and the promotion of cytochrome c release. In addition, CAR inhibited MDA-MB-231 cells migration. In vivo, CAR inhibited tumor growth in the 4T1 xenograft model without causing adverse effects and resulted in the mRNA upregulation caspase 9, p53, p21, and Beclin-1. In addition, CAR influenced the immune response by promoting the production of proinflammatory cytokines TNF-α, IFN-γ, IL-17, and IL-1β and increasing the percentage of TNF-α+, IL-17+, IL-1β+, and IFN-γ+ CD3+ splenocytes. In conclusion, compared with other antipsychotics, 5-FU, and cisplatin, CAR exerted the most potent anticancer activity in TNBC in vitro and in vivo. This efficacy may be attributed to its ability to regulate apoptosis and autophagy, promote G0/G1 cell cycle arrest, and modulate antitumor immune response, suggesting its therapeutic potential in breast cancer.

23 August 2024 in Plants
Verified
Journal Article
Open access
PDF file
TMTijana Marković
Tijana Marković
Suzana Lj. PopovićSuzana Lj. Popović
Suzana Lj. Popović
SMSanja D Matic
Sanja D Matic
MMMarina Mitrović
Marina Mitrović
MAMarijana Andjic
Marijana Andjic
Dejan BaskicDejan Baskic
Dejan Baskic
As cancer remains a significant global health challenge, there is an increasing need for novel therapeutic approaches. We investigated the antitumor potential of Juniperus communis berry essential oil on cervical cancer HeLa and colorectal HCT 116 cells. Cytotoxicity was evaluated through the MTT assay, revealing concentration-dependent reductions in cell viability. A clonogenic assay demonstrated long-term cytotoxic effects. Apoptosis markers were assessed via flow cytometric analysis and showed an induction of the intrinsic pathway in both cell lines, demonstrated by the elevated levels of cleaved caspase-3, Bax/Bcl-2 ratio, JC-10 monomer formation, and cytochrome C migration to the cytosol. The treatment inhibited cell-survival pathways in HCT 116 cells and arrested HeLa cells in the S phase. An extensive molecular docking screening provided insight into the binding affinity and interaction patterns of the essential oil components with NADH ubiquinone oxidoreductase and superoxide dismutase enzymes, further confirming the induction of the intrinsic pathway of apoptosis. The obtained in silico and in vitro results indicated the anticancer potential of J. communis berry essential oil as it interferes with cancer cell molecular mechanisms. Our findings highlight J. communis berry essential oil as a promising natural agent with anticancer potential.

18 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
UVUros Velickovic
Uros Velickovic
DSDragica Selakovic
Dragica Selakovic
NJNemanja Jovicic
Nemanja Jovicic
MMMarina Mitrović
Marina Mitrović
VJVladimir Janjic
Vladimir Janjic
GRGvozden Rosic
Gvozden Rosic
After 70 years of clinical practice with antipsychotics in the treatment of some specific serious mental disorders, much information has been accumulated considering their efficiency as a first-line evidence-based schizophrenia therapy, but also on their adverse effects within the range from minor to life-threatening issues. In this paper, we highlight motor impairment as a frequent limiting factor. Despite the diversity of side effects following antipsychotics usage, many of those who suffer share the same pathophysiological background issues, such as oxidative damage, neuroinflammation, apoptosis, and neurodegeneration (observed in the brain regions involved in motor control). The obvious need to solve these limitations is facing restraints in clinical studies due to the ethical issues. Therefore, it seems reasonable to address the importance of preclinical investigations to overcome the adverse effects of antipsychotics. For that purpose, we analyzed the antipsychotics-induced dyskinesia seen in rodent models, with a special focus on attempts to highlight the benefits of antioxidant supplementation. Our analysis has revealed that antioxidant supplementation, with various antioxidant-rich compounds, confirms the clear neuroprotective effects of the therapy of this iatrogenic dyskinesia. Given their accessibility and safety, it seems that the administration of antioxidant-rich compounds in various forms, as an adjuvant therapy, may be beneficial in patients by lowering the risk of secondary Parkinsonism. Also, it seems that the strategy for further investigations in this field of preclinical studies should be standardized and should include more antipsychotics employed in the clinical practice.

1 August 2016 in Int. Journal of Clinical Pharmacology and Therapeutics
Verified
Journal Article
Closed access
MAMarija Andjelkovic
Marija Andjelkovic
SJSlobodan Janković
Slobodan Janković
MMMarina Mitrović
Marina Mitrović
VMVioleta Mladenovic
Violeta Mladenovic
INIvana Nikolic
Ivana Nikolic
MFMarko Folic
Marko Folic
Hypothyroidism is one of most common endocrine disorders resulting from deficiency of thyroid hormones. The aim of our study was to investigate whether cardiovascular drugs as well as gender, age, body-mass index, and habits, like smoking or drinking coffee affect thyroid-stimulating hormone (TSH) level in hypothyroid patients with thyroxine replacement therapy who suffer from cardiovascular disease.